Shares of Chemours (CC) tumbled 5.20% in after-hours trading on Thursday following the release of its third-quarter 2025 financial results, which fell short of analysts' expectations. The chemical company's disappointing earnings report and weak outlook for the fourth quarter triggered a sell-off among investors.

Chemours reported adjusted earnings per share (EPS) of $0.20 for Q3, significantly missing the consensus estimate of $0.28. The company's sales for the quarter came in at $1.5 billion, slightly below the expected $1.502 billion. Additionally, Chemours' adjusted net income of $30 million fell well short of analysts' projections of $43.2 million, further contributing to investor concerns.

Adding to the negative sentiment, Chemours provided a cautious outlook for the fourth quarter, anticipating a 10-15% sequential decrease in consolidated net sales due to seasonal impacts. This forecast suggests continued challenges for the company in the near term, likely prompting investors to reassess their positions. Despite the overall disappointing results, it's worth noting that the company's adjusted EBITDA of $195 million did surpass the estimated $185.5 million, offering a slight silver lining amidst the otherwise gloomy report.